Last reviewed · How we verify
Signifor
At a glance
| Generic name | Signifor |
|---|---|
| Also known as | ATC-Code: H01CB05 |
| Sponsor | University Hospital Heidelberg |
| Target | Somatostatin receptor type 1, Somatostatin receptor type 2, Somatostatin receptor type 3 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Hypercortisolism
Common side effects
- Diarrhea
- Hyperglycemia
- Nausea
- Cholelithiasis
- Headache
- Abdominal pain
- Fatigue
- Diabetes mellitus
- Increased HbA1c
- Type 2 diabetes mellitus
- Vomiting
- Anemia
Serious adverse events
- Serious adverse events (overall)
- Adverse events leading to study discontinuation
Key clinical trials
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (PHASE3)
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
- Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment (PHASE2)
- Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer (PHASE2)
- Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor (PHASE2)
- Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (PHASE4)
- Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |